RA trial will compare UCB's Cimzia and Abbott's Humira

05/25/2011 | Wall Street Journal, The

UCB will perform a 12-week clinical study to compare the efficacy of flagship product Cimzia with Abbott Laboratories' best-seller Humira in patients with rheumatoid arthritis. Both are injectable drugs that work by inhibiting tumor necrosis factor. "We believe the study will provide additional evidence that the ability to make an informed and early treatment decision is important for the treatment of this severe and progressing disease," said Iris Loew-Friedrich, UCB's chief medical officer.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC